ESR1 and breast carcinoma: In postmenopausal women, CLA can inhibit the estrogen receptor (ER) signaling in human endometrial and breast cancer cells [22], acting as an estrogen antagonist through the inhibition of ER alpha (ERa)-mediated responses.